



January 27, 2023

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 051

Scrip Code: **530019**

Symbol: **JUBLPHARMA**

Dear Sirs,

**Sub.: Schedule of Investor Conference Call for Jubilant Pharmova Limited -
Unaudited Financial Results for the quarter and nine months ended
December 31, 2022**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on February 3, 2023 after submission of the financial results for the quarter and nine months ended December 31, 2022 to the Stock Exchanges. Details of the Conference Call are attached.

This is for information and record.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited

Naresh Kapoor
Company Secretary

Encl. a/a

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624




Jubilant Pharmova Limited
1A, Sector 16A, Noida – 201301, India
Tel.: +91 120 4361000
www.jubilantpharmova.com

Noida, Friday, 27th Jan, 2023

Conference call on Friday, Feb 03, 2023 at 05:00 pm IST

Jubilant Pharmova Limited, engaged in Radiopharma, Allergy Immunotherapy, CDMO of Sterile Injectable, Generics, Contract Research Development and Manufacturing (CRDMO) and Proprietary Novel Drugs businesses, will host a conference call for analysts and investors on Friday, Feb 03, 2023, at 05:00 PM IST. The call will commence with a brief management discussion on the financial performance for the quarter ended December 31, 2022, followed by an interactive Question & Answer session.

Diamond Pass Log-In	
Pre-registration:	<p>To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.</p> <p> Click here to ExpressJoin the Call</p> <p>You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call.</p>
Conference Dial-In Numbers	
Universal Access:	+ 91 22 6280 1141 + 91 22 7115 8042
Toll Free Number:	USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448
Replay Facility:	Available from February 03 to February 10, 2023 Dial in No.: +91 22 7194 5757 / +91 22 6663 5757 Playback ID: 41519

-ENDS -

About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in Specialty Pharmaceuticals, Contract Research, Development and Manufacturing (CRDMO), CDMO-Sterile Injectables, Generics and Proprietary Novel Drugs businesses. Specialty Pharmaceuticals, CDMO and Generics businesses through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of radiopharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Generics/branded formulation. JPL has five manufacturing facilities that cater to all the regulated markets including USA, Europe and other geographies. Jubilant Biosys Limited provides contract research and development services with two world class research centres in Bangalore and Noida in India. Jubilant Pharmova Limited is also involved in manufacturing of Active Pharmaceutical Ingredients (API) from its USFDA approved facility in Nanjangud, India. Jubilant Therapeutics is involved in Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and autoimmune disorders. Jubilant Pharmova Limited has a team of over 6,000 multicultural people across the globe. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals companies globally. For more information, please visit: www.jubilantpharmova.com

For more information please contact:

Surajit Pal, Vineet V Mayer
Jubilant Pharmova Limited
Ph: +91-120 4361002, 1103
E-mail: surajit.pal1@jubl.com
vineet.mayer@jubl.com

Siddharth Rangnekar / Mit Shah
CDR India
Ph: +91 97699 19966 / 99201 68314
E-mail: siddharth@cdr-india.com
mit@cdr-india.com

Disclaimer: Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

